WVE WAVE Life Sciences

WAVE Life Sciences to Present at Upcoming Investor Conferences

WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be participating at the following upcoming investor conferences:

  • Jefferies 2017 Global Healthcare Conference – WAVE Company Presentation

    Wednesday, June 7th at 1:30 P.M. ET – New York
  • The JMP Securities Life Science Conference – Company Panel Discussion: Neuromuscular Disorders

    Tuesday, June 20th at 2:00 P.M. ET – New York

A live webcast of the WAVE company presentation at the Jefferies 2017 Global Healthcare Conference will be available on the investor relations page of the WAVE Life Sciences corporate website at http://ir.wavelifesciences.com. A replay will remain archived on the corporate website for a limited time.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize rationally redesigned nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

 PRESS RELEASE

Wave Life Sciences Announces Virtual Research Day on October 29th and ...

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. In addition, members of Wave’s management team are scheduled to participate in several upcoming investor conferences. Details are as follows: Bernstein 2...

 PRESS RELEASE

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion...

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)  First-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during a non-drug related acute phase response (20.6 µM total AAT, 10.3 µM M-AAT) Single dose of 400 mg achieved 12.8 µM total AAT and 5.3 µM M-AAT; ongoing 400 mg m...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch